Immuron Limited Sponsored ADR IMRN 深 滬
等待開盤 03-27 09:30:00 美东时间
0.7879
+0.017
+2.26%
華盛通- 最 高0.824
- 今 開0.824
- 成交量 6868股
- 最 低 0.77
- 昨 收 0.7705
- 總市值 643.42万
- 52周最高 2.39
- 市盈率 靜 --
- 換手率 0.08%
- 52周最低 0.6765
- 委 比 0.00%
- 總股本 816.63万
- 歷史最高 28.99
- 量 比 1.11
- 振 幅 7.01%
- 歷史最低 0.6765
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
Immuron Limited's CEO, Steven Lydeamore, is presenting at the Coffee Microcaps Conference on March 5, 2026. Immuron, an Australian biopharmaceutical company, focuses on developing orally delivered polyclonal antibodies for infectious diseases. Its product Travelan® is an oral immunotherapy to prevent travelers’ diarrhea and is approved in Australia, Canada, and the U.S. as a dietary supplement. IMM-529, another product, targets recurrent Clostrid...
03-05 11:00
Immuron HY26 net loss narrows 22.9% to AUD 1.9 million
Immuron HY26 net loss narrows 22.9% to AUD 1.9 million Immuron reported HY26 revenue from ordinary activities of AUD 4.2 million, up 4.8%, and a loss after tax attributable to shareholders of AUD 1.9 million, down 22.9%, for the six months ended 31 December 2025. Net tangible assets were 3.94 cents
03-02 19:10
Immuron H1 EPS $(0.01), Same YoY, Sales $4.184M Up From $3.994M YoY
Immuron (NASDAQ:IMRN) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.184 million in sales this quarter. This is a 4.76 percent increase over
02-25 21:26
BRIEF-Immuron Reports Hy26 Results And Strategic Reset
BRIEF-Immuron Reports Hy26 Results And Strategic Reset Feb 25 (Reuters) - Immuron Ltd IMC.AX : IMMURON REPORTS HY26 RESULTS AND STRATEGIC RESET IMMURON LTD: TAKEN A STRATEGIC DECISION TO PURSUE PARTNERSHIPS TO FUND PROGRESS OF TRAVELAN AND IMM-529 CLINICAL PROGRAMS Source text: ID:nGNX5F39D5 Furthe
02-25 19:26
Immuron reports 1H results
Immuron press release (IMRN): 1H record sales of A$4.2 million, up 5% on HY25. EPS of -A$0.70 More on Immuron Immuron Limited (IMRN) Presents at Emerging Growth Conference 89 - Slideshow Seeking Alpha...
02-25 19:14
Immuron Reports Continued Sales Growth
Immuron Limited reported H1 sales growth of Travelan® and ProIBS® across key markets. Global H1 sales reached AUD$4.2 million, up 5% YoY, with Australia leading at AUD$3.3 million (+13%) and the U.S. at AUD$0.9 million (+17%). Canada saw Q2 sales surge 191% after a slow start. ProIBS® launched in Australia ahead of schedule and will expand in Canada, targeting increased consumer awareness. The company attributes growth to marketing efforts, new s...
01-19 11:00
Immuron shares are trading lower after the topline results from a clinical trial of IMM‑124E failed to meet the primary endpoint.
Immuron shares are trading lower after the topline results from a clinical tria...
2025-12-11 03:43
Immuron Announces A New Research Agreement With The Naval Medical Research Command And The Walter Reed Army Institute Of Research, Funded By U.S. Department Of Defense Subaward
As previously announced on August 16, 2024, the Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting
2025-12-03 19:02
Immuron Secures U.S. Defense Award for Diarrheal Disease Therapeutics
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited has a...
2025-12-03 10:47
Immuron Limited Director Increases Stake with Shareholder Approval
Immuron Limited ( ($AU:IMC) ) has issued an announcement. Immuron Limited annou...
2025-11-21 16:05
